These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6141614)

  • 21. Association of intellectual impairment, negative symptoms, and aging with tardive dyskinesia: clinical and animal studies.
    Waddington JL; Youssef HA; Molloy AG; O'Boyle KM; Pugh MT
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):29-33. PubMed ID: 2858476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of tardive dyskinesia development: preliminary results.
    Kane JM; Woerner M; Weinhold P; Wegner J; Kinon B
    J Clin Psychopharmacol; 1982 Oct; 2(5):345-9. PubMed ID: 6127353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
    Cohen S; Khan A; Zheng Y; Chiles J
    Acta Psychiatr Scand; 1991 Mar; 83(3):234-7. PubMed ID: 1674398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnosis of rapid abnormal involuntary movements associated with fluphenazine decanoate.
    Glazer WM; Moore DC
    J Nerv Ment Dis; 1980 Jul; 168(7):439-41. PubMed ID: 7400795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluphenazine decanoate and tardive dyskinesia.
    Schiff AA
    Am J Psychiatry; 1982 Jul; 139(7):969-70. PubMed ID: 6124136
    [No Abstract]   [Full Text] [Related]  

  • 27. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Schizophr Res; 1991; 4(2):109-20. PubMed ID: 1674881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.
    Waddington JL; Youssef HA; Dolphin C; Kinsella A
    Arch Gen Psychiatry; 1987 Oct; 44(10):907-12. PubMed ID: 2889438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is tardive dyskinesia a unique disorder?
    Marsden CD
    Psychopharmacology Suppl; 1985; 2():64-71. PubMed ID: 2860661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia: prevalence, incidence, and risk factors.
    Kane JM; Woerner M; Lieberman J
    Psychopharmacology Suppl; 1985; 2():72-8. PubMed ID: 2860662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
    Linn GS; Lifshitz K; O'Keeffe RT; Lee K; Camp-Lifshitz J
    Psychopharmacology (Berl); 2001 Jan; 153(3):285-94. PubMed ID: 11271400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
    Sachdev P; Tang WM
    Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.
    Diehl A; Reinhard I; Schmitt A; Mann K; Gattaz WF
    Eur Psychiatry; 2009 Jan; 24(1):33-40. PubMed ID: 18774276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics.
    Altamura AC; Cavallaro R; Regazzetti MG
    Eur Arch Psychiatry Clin Neurosci; 1990; 240(1):9-12. PubMed ID: 1979540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
    Domino EF
    Psychopharmacology Suppl; 1985; 2():217-23. PubMed ID: 2860660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.